Agilon health Q4 net loss $230M, medical margin negative $102M; FY2024 guidance slashed

agilon health, inc.

Q4 revenue $1.06B (+72% YoY) but gross profit of negative $95M vs $16M a year ago.
Full-year 2023 net loss $263M vs $107M in 2022; Adjusted EBITDA loss $95M.
Medical margin for Q4 negative $102M; FY2023 $299M vs guidance midpoint $350M.
FY2024 medical margin guidance cut to $400-450M from prior $560-600M; Adj. EBITDA now loss of $60-15M vs prior profit $40-60M.
Class of 2025 adds at least 60K MA members across 5 physician groups; entry costs lowered to $55-65M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.96

agilon health, inc. reported the three and twelve months ended December 31, 2023 results: revenue Total revenue of $1.06 billion in the fourth quarter 2023 increased 72% compared to $615 million in the fourth quarter 2, net income Net loss of $230 million in the fourth quarter 2023 compared to a loss of $57 million in the fourth quarter 2022. For th. Guidance reaffirmed.

Period: the three and twelve months ended December 31, 2023
Revenue: Total revenue of $1.06 billion in the fourth quarter 2023 increased 72% compared to $615 million in the fourth quarter 2
Net income: Net loss of $230 million in the fourth quarter 2023 compared to a loss of $57 million in the fourth quarter 2022. For th
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 27, 2024 , agilon health, inc. (“agilon” or the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and twelve months ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

agilon health, inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-007195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.